Chiasma Announces FDA Acceptance of Mycapssa New Drug Application Resubmission

NEEDHAM, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that the U.S. Food and Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news